| Q36631246 | Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected] |
| Q24529092 | Branched polyamines cure prion-infected neuroblastoma cells |
| Q57083642 | Chapter 10 Prions |
| Q36653932 | Congo red inhibition of scrapie agent replication |
| Q39868476 | Congo red prolongs the incubation period in scrapie-infected hamsters. |
| Q33847297 | Deletion of beta-strand and alpha-helix secondary structure in normal prion protein inhibits formation of its protease-resistant isoform |
| Q28485431 | Discovery of a novel, monocationic, small-molecule inhibitor of scrapie prion accumulation in cultured sheep microglia and Rov cells |
| Q37191835 | Effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prions. |
| Q33645704 | Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing Syrian hamster PrP only in neurons |
| Q41753130 | Enhancement of enterovirus infectivity in vitro by pretreating host cell monolayers with the cationic polymer polyethyleneimine |
| Q24682427 | Evaluation of quinacrine treatment for prion diseases |
| Q36870379 | Experimental drug treatment of scrapie: A pathogenetic basis for rationale therapeutics |
| Q34625274 | Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? |
| Q33539797 | Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring |
| Q40474826 | Glycosylation-related gene expression in prion diseases: PrPSc accumulation in scrapie infected GT1 cells depends on beta-1,4-linked GalNAc-4-SO4 hyposulfation. |
| Q34976098 | Inhibition of Protease-Resistant Prion Protein Accumulation In Vitro by Curcumin |
| Q33818879 | Inhibition of prion-protein conversion: a therapeutic tool? |
| Q36518232 | Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines |
| Q40654314 | Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis |
| Q39005891 | Insights from Therapeutic Studies for PrP Prion Disease |
| Q34304967 | Interactions and conversions of prion protein isoforms |
| Q42090343 | Intraperitoneal infection with scrapie is established within minutes of injection and is non-specifically enhanced by a variety of different drugs |
| Q64447659 | Involvement of the immune system in TSE pathogenesis |
| Q24525199 | Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation |
| Q74140633 | Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update |
| Q36080838 | Modulation of Glycosaminoglycans Affects PrPSc Metabolism but Does Not Block PrPSc Uptake. |
| Q36676179 | Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy |
| Q33805383 | Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent |
| Q68424144 | Pathogenesis of hamster scrapie. Adherent splenocytes are associated with relatively high levels of infectivity |
| Q58277839 | Polyanion induced fibril growth enables the development of a reproducible assay in solution for the screening of fibril interfering compounds, and the investigation of the prion nucleation site |
| Q28359788 | Polysaccharides as antiviral agents: antiviral activity of carrageenan |
| Q74499436 | Postexposure prophylaxis against transmissible spongiform encephalopathies: CpG oligodeoxynucleotides in mice |
| Q34509751 | Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides |
| Q60155097 | Prion Diseases |
| Q59419884 | Prion Protein Interaction with Glycosaminoglycan Occurs with the Formation of Oligomeric Complexes Stabilized by Cu(II) Bridges |
| Q36693364 | Prion detection by an amyloid seeding assay. |
| Q35906120 | Prion diseases--close to effective therapy? |
| Q37798877 | Prion protein self-interactions: a gateway to novel therapeutic strategies? |
| Q48220367 | Prions and related neurological diseases |
| Q74452125 | Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies |
| Q35990277 | Rational targeting for prion therapeutics. |
| Q33722019 | Sulfated dextrans enhance in vitro amplification of bovine spongiform encephalopathy PrP(Sc) and enable ultrasensitive detection of bovine PrP(Sc). |
| Q39673524 | Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein |
| Q36640586 | Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells |
| Q41987801 | Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment |
| Q35652778 | Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions |
| Q30531528 | Tetracyclines affect prion infectivity |
| Q35050425 | The transmissible spongiform encephalopathies: pathogenic mechanisms and strategies for therapeutic intervention |
| Q36901944 | Therapeutic approaches for prion disorders |
| Q35122351 | Therapeutic approaches to prion diseases. |
| Q37557690 | Therapeutic interventions ameliorating prion disease |
| Q34306678 | Transmissible spongiform encephalopathies and prion protein interconversions |
| Q39590279 | Tumor necrosis factor alpha-deficient, but not interleukin-6-deficient, mice resist peripheral infection with scrapie |